You are here: Industry Insights > Asthma

News List

Novel molecules to combat asthma and COVID-related lung diseases discovered worldpharmanews
January 28, 2021
A study designed to study how the immune system impacts gut bacteria - has led to the extraordinary discovery of two molecules that can not only provide profound protection in experimental models of asthma but can also substantially reduce the ...
AZ, Amgen’s SOURCE trial misses primary endpoint pharmatimes
December 23, 2020
AstraZeneca and Amgen have announced that a phase III trial of their new medicine tezepelumab failed to meet the primary endpoint in patients with severe, oral corticosteroid-dependent asthma.
AstraZeneca’s Asthma drug Benralizumab gets marketing approval from DCGI expresspharma
December 23, 2020
Fasenra is an add-on maintenance treatment for patients with severe eosinophilic asthma.
Vectura, Kinaset Therapeutics set to develop inhaled asthma drug pharmatimes
December 03, 2020
UK-based Vectura Group has signed an agreement with Kinaset Therapeutics to develop and commercialise a preclinical inhaled pan-JAK inhibitor for the treatment of severe asthma.
Vectura, Kinaset Partner to Develop Asthma Treatment contractpharma
December 01, 2020
Licenses VR588 to Kinaset, Vectura will provide formulation development services to support Phase I studies and ultimately commercialization.
Tezepelumab Trial Meets Primary Endpoint americanpharmaceuticalreview
November 20, 2020
Amgen and AstraZeneca announced positive topline results from the Phase 3 NAVIGATOR trial in which the investigational medicine tezepelumab demonstrated a statistically significant reduction in exacerbations compared to placebo in patients with severe ...
Amgen, AZ’s asthma drug tezepelumab scores phase III win pharmatimes
November 12, 2020
Amgen and AstraZeneca’s (AZ) experimental asthma drug tezepelumab has scored a phase III win in severe, uncontrolled asthma.
AptarGroup Acquires Assets of Cohero Health contractpharma
November 06, 2020
AptarGroup Inc., an expert in consumer dispensing, active packaging, drug delivery solutions and services, has acquired all operating assets and the proprietary portfolio of Cohero Health Inc., a digital therapeutics company transforming respiratory ...
FASENRA eliminated OCS in a majority of asthma patients in PONENTE Phase IIIb trial expresspharma
October 30, 2020
High-level results from the PONENTE Phase IIIb open-label trial showed FASENRA (benralizumab) eliminated the use of maintenance oral corticosteroids (OCS) in OCS-dependent asthma patients with a broad range of blood eosinophil counts.
Asthma fund launched to support development and adoption of new technologies pharmatimes
October 22, 2020
A new fund aiming to support the development and adoption of technology for people with asthma has been created by Asthma UK and the British Lung Foundation alongside the National Institute for Health Research (NIHR) and the Engineering and ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page